External validation of 2 prognostic indices for patients with advanced pancreatic cancer treated with first-line therapy

Pancreas

Volumn 41, Issue 5, 2012, Pages 738-744

  Haas, Michael ^a   Laubender, Ruediger P ^b   Klose, Christina ^c   Schulz, Christoph ^a   Mansmann, Ulrich ^b   Boeck, Stefan ^a   Heinemann, Volker ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Advanced pancreatic cancer; First line therapy; Prognostic index

Indexed keywords

BILIRUBIN; C REACTIVE PROTEIN; CA 19-9 ANTIGEN; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; ERLOTINIB; GEMCITABINE; HEMOGLOBIN; LACTATE DEHYDROGENASE;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; ASIAN; BILIRUBIN BLOOD LEVEL; BRIER SCORE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; DISTANT METASTASIS; DRUG EFFICACY; EXTERNAL VALIDITY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; ISHII SCORE; KAPLAN MEIER METHOD; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS CANCER; PREMEDICATION; PRIORITY JOURNAL; SAWAKI SCORE; SCORING SYSTEM; TREATMENT DURATION; TUMOR GROWTH; TUMOR LOCALIZATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; C-REACTIVE PROTEIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PANCREATIC NEOPLASMS; PROGNOSIS; PROSTATE; REPRODUCIBILITY OF RESULTS;

EID: 84863722832     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31823bcc7b     Document Type: Article

References (20)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics. CA Cancer J Clin. 2010;60:277-300.
2. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
3. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1997;25:1960-1966.
4. Philip PA, Mooney M, Jaffe D, et al. Consensus report of the National Cancer Institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol. 2009;27:5660-5669.
5. Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol. 2010;7:163-172.
6. Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006;24:3946-3952.
7. Boeck S, Hinke A, Wilkowski R, et al. Importance of performance status for treatment outcome in advanced pancreatic cancer. Wo r l d J Gastroenterol. 2007;13:224-227.
8. Stocken DD, Hassan AB, Altman DG, et al. Modelling prognostic factors in advanced pancreatic cancer. Br J Cancer. 2008;99:883-893.
9. van Cutsem E, van de Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 2004;22:1430-1438.
10. van Cutsem E, Vervenne WL, Bennouna J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol. 2009;27:2231-2237.
11. Ishii H, Okada S, Nose H, et al. Prognostic factors in patients with advanced pancreatic cancer treated with systemic chemotherapy. Pancreas. 1996;12:267-271.
12. Sawaki A, Kanemitsu Y, Mizuno N, et al. Practical prognostic index for patients with metastatic pancreatic cancer treated with gemcitabine. J Gastroenterol Hepatol. 2008;23:1292-1297.
13. Boeck S, Haas M, Laubender RP, et al. Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer. Clin Cancer Res. 2010;16:986-994.
14. Graf E, Schmoor C, Sauerbrei W, et al. Assessment and comparison of prognostic classification schemes for survival data. Stat Med. 1999;18:2529-2545.
15. Tanaka T, Ikeda M, Okusaka T, et al. Prognostic factors in Japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy. Jpn J Clin Oncol. 2008;38:755-761.
16. Maréchal R, Demols A, Gay F, et al. Prognostic factors and prognostic index for chemonaBve and gemcitabine-refractory patients with advanced pancreatic cancer. Oncology. 2007;73:41-51.
17. Storniolo AM, Enas NH, Brown CA, et al. An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer. 1999;85:1261-1268.
18. Cubiella J, Castells A, Fondevila C, et al. Prognostic factors in nonresectable pancreatic adenocarcinoma: a rationale to design therapeutic trials. Am J Gastroenterol. 1999;94:1271-1278.
19. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regressions: a bad idea. Stat Med. 2006;25:127-141.
20. Boeck S, Vehling-Kaiser U, Waldschmidt D, et al. Gemcitabine plus erlotinib (GE) followed by capecitabine (C) versus capecitabine plus erlotinib (CE) followed by gemcitabine (G) in advanced pancreatic cancer (APC)-a randomized, cross-over phase III trial of the "Arbeitsgemeinschaft Internistische Onkologie" (AIO). Proc Am Soc Clin Oncol. 2010;28 (7 s). Abstract LBA4011.